As part of its reorganization around key therapy areas of oncology and immunology, Belgian biotech Galapagos (Euronext: GLPG) is hiving off certain research functions.
The company has reached a deal with French contract research organization (CRO) NovAliX to transfer ownership of its R&D operations in Romainville, France.
With new leadership, Galapagos has acquired biotech firms CellPoint and AboundBio as part of a move into the development of next-generation cell therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze